QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences
Rhea-AI Summary
QuidelOrtho (Nasdaq: QDEL) announced that its management team will participate in two June 2026 investor conferences. The company will present at the William Blair 46th Annual Growth Stock Conference on June 2 at 12:20 p.m. ET and join a fireside chat at the Jefferies Global Healthcare Conference on June 3 at 8:10 a.m. ET. Live webcasts and replays will be available in the “Events & Presentations” section of QuidelOrtho’s Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – QDEL
In the May 20 session, QDEL gained 4.66%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Negative | -6.0% | Weaker Q1 results and lowered 2026 guidance pressured the stock. |
| Apr 23 | Educational podcast | Neutral | -5.5% | Science Bytes episode on U.S. syphilis trends and screening gaps. |
| Apr 20 | LEX sale announcement | Positive | +1.4% | Announcement that QuidelOrtho would acquire LEX Diagnostics and VELO platform. |
| Apr 20 | LEX acquisition close | Positive | +1.4% | Completion of roughly $100M LEX Diagnostics acquisition expanding PCR portfolio. |
| Apr 15 | Prelim Q1 and guidance | Negative | -27.5% | Preliminary Q1 revenue miss and lower outlook triggered a sharp sell-off. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows negative fundamental updates often met with aligned sell-offs, while strategic/acquisition news has seen modest positive alignment.
Over the last months, QDEL has reported softer fundamentals and strategic moves. Preliminary Q1 2026 revenue of $615–$620 million and weaker guidance on Apr 15 led to a -27.47% reaction. The May 5 10-Q confirmed Q1 revenue of $619.8 million and wider losses, with shares down 6%. In contrast, the completion of the $100 million LEX Diagnostics acquisition and related news on Apr 20 drew modest gains of 1.42%. Today’s conference participation notice fits the pattern of routine corporate communications rather than a major catalyst.
Key Terms
in vitro diagnostics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026
Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT.
Jefferies Global Healthcare Conference, Wednesday, June 3, 2026
Members of QuidelOrtho's management team will participate in a fireside chat at 8:10 a.m. ET / 5:10 a.m. PT.
Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
Stephanie Kleewein
Senior Corporate Communications and PR Manager
media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-to-participate-in-upcoming-june-2026-investor-conferences-302777345.html
SOURCE QuidelOrtho Corporation